CathWorks

CathWorks

FFRangio®

FFRangio®

System employs drug-free, wire-free technology for comprehensive physiological assessment

系统采用无药物、无导线技术进行全面生理评估

GALWAY, Ireland

爱尔兰戈尔韦

,

，

April 20, 2026

2026年4月20日

/

/

PRNewswire

美通社

/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it has completed its acquisition of CathWorks, a privately held medical device company, which aims to transform how coronary artery disease (CAD) is diagnosed and treated. The acquisition follows a 2022 strategic partnership with a co-promotion agreement for the CathWorks FFRangio® System where it is commercially available in the U.S., Europe and Japan. The acquisition is valued at $585 million with potential undisclosed earn-out payments post-acquisition..

/ -- 全球医疗技术领导者美敦力公司（纽约证券交易所代码：MDT）今天宣布，已完成对私营医疗器械公司CathWorks的收购，该公司致力于改变冠状动脉疾病（CAD）的诊断和治疗方法。此次收购是在2022年一项战略合作伙伴关系之后进行的，该合作包括针对CathWorks FFRangio®系统在美国、欧洲和日本商业化推广的联合推广协议。此次收购价值5.85亿美元，并可能在收购后支付未披露的额外收益款项。

'With the acquisition of CathWorks by Medtronic, we are boldly redefining the future of cardiovascular care,' said Ramin Mousavi, president and chief executive officer of CathWorks. 'As I reflect on our long-term partnership, I am deeply grateful and proud of what we've accomplished together. This deal is a testament to CathWorks' and Medtronic's shared commitment, vision, and relentless drive to revolutionize the cath lab and deliver better solutions for patients living with cardiovascular disease.

“随着美敦力收购CathWorks，我们正在大胆重新定义心血管护理的未来，”CathWorks总裁兼首席执行官拉明·穆萨维表示。“回顾我们的长期合作关系，我深感感激并为我们共同取得的成就感到自豪。此次交易证明了CathWorks和美敦力共同的承诺、愿景以及彻底变革导管实验室、为心血管病患者提供更好解决方案的不懈追求。”

Together, we have ushered in a new dawn in cardiovascular diagnosis and patient outcomes.'.

我们一起迎来了心血管诊断和患者预后的新曙光。

Using a combination of artificial intelligence (AI) and advanced computational science, the CathWorks FFRangio System provides a comprehensive physiological assessment of the entire coronary tree directly from routine drug-free, wire-free coronary angiograms (X-rays). This differs from traditional wire-based fractional flow reserve (FFR) assessment, which is invasive and requires the use of pressure wires, pharmacologic hyperemia, and measurements limited to a single transducer location within the vessel.

结合人工智能 (AI) 和先进的计算科学，CathWorks FFRangio 系统能够直接从常规的无药物、无导丝冠状动脉造影（X 光）中提供对整个冠状动脉树的全面生理评估。这不同于传统的基于导丝的血流储备分数 (FFR) 评估，后者具有侵入性，需要使用压力导丝、药物诱导的充血以及局限于血管内单个传感器位置的测量。

.

。

Today's announcement follows CathWorks' recent one-year results from its landmark ALL-RISE randomized control trial at the 2026 American College of Cardiology conference. The trial, including more than 1,900 patients across 59 sites in North America, Asia, Europe and the Middle East, demonstrated that CathWorks FFRangio is non-inferior to wire-based physiology in terms of major adverse cardiac events (MACE) at one year, with improved resource utilization and reduced procedure time benefits..

今天的公告紧随CathWorks近期在2026年美国心脏病学会会议上发布的其里程碑式ALL-RISE随机对照试验的一年结果。该试验涵盖北美、亚洲、欧洲和中东59个地点的1900多名患者，显示CathWorks FFRangio在一年主要不良心脏事件（MACE）方面不劣于基于导线的生理学检测，同时提升了资源利用效率并减少了手术时间。

1

1

'The acquisition of CathWorks significantly enhances Medtronic's interventional cardiology portfolio with an innovative system that empowers physicians with data-driven insights for the diagnosis and treatment of coronary artery disease,' said Jason Weidman, senior vice president and president of the Coronary & Renal Denervation business, part of the Cardiovascular Portfolio at Medtronic.

“收购CathWorks极大地增强了美敦力的介入心脏病学产品组合，该创新系统为医生提供了数据驱动的洞察力，用于冠状动脉疾病的诊断和治疗，”美敦力心血管产品组合部门冠状动脉与肾去神经业务高级副总裁兼总裁Jason Weidman表示。

'Through our global footprint, welcoming CathWorks to Medtronic will expand access to the transformative FFRangio technology for our customers and their patients worldwide.'.

“通过我们的全球影响力，欢迎CathWorks加入美敦力，将为我们的客户及其全球患者扩大获得变革性的FFRangio技术的机会。”

This agreement continues Medtronic's momentum in executing on strategic deals that strengthen the company's leadership within its core franchises. Medtronic continues to prioritize high-growth merger and acquisition opportunities to complement its core businesses and deliver sustained value for its physician and hospital partners. .

该协议继续推动美敦力在执行加强公司核心业务领导地位的战略交易上保持前进的势头。美敦力将继续优先考虑高增长的并购机会，以补充其核心业务，并为其医生和医院合作伙伴提供持续的价值。

'The acquisition of CathWorks is the latest example of our commitment to purposeful investment and strategic tuck-in acquisitions to advance the Medtronic innovation strategy,' said Skip Kiil, executive vice president and president, Cardiovascular portfolio at Medtronic. 'This positions Medtronic at the forefront of digital transformation in cardiovascular, allowing us to deliver next-generation solutions for physicians and their patients.'.

“收购CathWorks是我们致力于有意义的投资和战略性补强收购以推动美敦力创新战略的最新例证，”美敦力执行副总裁兼心血管产品组合总裁Skip Kiil表示。“这使美敦力处于心血管数字化转型的前沿，让我们能够为医生及其患者提供下一代解决方案。”

Financial Highlights

财务亮点

This acquisition is expected to be immaterial to Medtronic's fiscal year 2027 GAAP and adjusted earnings per share and neutral to accretive thereafter.

此次收购预计对美敦力2027财年的GAAP和调整后每股收益影响不大，此后将保持中性或增值。

About FFRangio

关于FFRangio

Using a combination of AI and advanced computational science, the CathWorks FFRangio® System is the only angiography-derived system that delivers FFR values along the entire coronary tree. In addition, the system provides information that helps physicians select the appropriate device size for treatment, and data that calculates the impact of lesion treatment.

结合人工智能和先进的计算科学，CathWorks FFRangio® 系统是唯一一个能够沿整个冠状动脉树提供FFR值的血管造影衍生系统。此外，该系统还提供了帮助医生选择合适治疗设备尺寸的信息，以及计算病灶治疗影响的数据。

Together, these capabilities empower physicians with deeper physiological insights to support confident, patient-centered treatment decisions.*.

这些能力相结合，赋予医生更深入的生理学见解，以支持他们做出有信心的、以患者为中心的治疗决策。*

About CathWorks

关于CathWorks

CathWorks, founded in Kfar Saba, Israel, is the leader in coronary digital health innovations that can improve the lives of patients globally. The CathWorks FFRangio® System combines artificial intelligence and advanced computational science, transforming how cardiovascular disease is diagnosed and treated.

CathWorks 总部位于以色列卡法萨巴，是冠状动脉数字健康创新领域的领导者，其创新技术可以改善全球患者的生活。CathWorks FFRangio® 系统结合了人工智能和先进的计算科学，彻底改变了心血管疾病的诊断和治疗方式。

The FFRangio System obtains physiologic information from routine angiograms, eliminating the need for drug stimulation and invasive pressure wires. It provides physicians with quick.

FFRangio系统从常规血管造影中获取生理信息，无需药物刺激和侵入性压力导丝。它为医生提供快速的信息。

2

2

and reliable

可靠

3

3

intraprocedural FFR values for the entire coronary tree. For more information on CathWorks, visit

整个冠状动脉树的术中FFR值。有关CathWorks的更多信息，请访问

www.cath.works

www.cath.works

and follow

跟随

@CathWorks

@CathWorks

on

在

LinkedIn

领英

.

。

About Medtronic

美敦力公司简介

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.

大胆思考。更果敢的行动。我们是美敦力。美敦力公司总部位于爱尔兰戈尔韦，是全球领先的医疗技术公司，通过寻找并发现解决方案，大胆应对人类面临的最具挑战性的健康问题。我们的使命——减轻病痛、恢复健康、延长生命——将遍布150多个国家的95,000多名充满热情的员工团结在一起。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和疗法治疗70种健康状况，包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监测系统等。凭借我们多样化的知识、无尽的好奇心和帮助所有需要帮助的人的愿望，我们提供了创新的技术，每秒、每小时、每一天都在改变两个人的生活。

Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit .

期待我们带来更多的成果，因为我们致力于推动以洞察力为基础的护理、以人为本的体验，以及为世界创造更好的结果。在我们所做的一切中，我们正在创造非凡的工程。如需更多关于美敦力的信息，请访问。

www.Medtronic.com

www.美敦力.com

and follow Medtronic on

并关注美敦力

LinkedIn

领英

.

。

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

任何前瞻性陈述均受风险和不确定性的影响，例如美敦力公司向证券交易委员会提交的定期报告中描述的那些。实际结果可能与预期结果有重大差异。

*FFRangio values generated by the

*FFRangio 值由

CathWorks FFRangio®

CathWorks FFRangio®

system are intended to be used by qualified clinicians in conjunction with the patient's clinical history, symptoms, and other diagnostic tests, as well as the clinician's professional evaluation.

系统旨在由合格的临床医生结合患者的临床病史、症状、其他诊断测试，以及临床医生的专业评估一起使用。

1. F. Fearon, W M.D., et al. Angiography-Derived Fractional Flow Reserve to Guide PCI.

1. F. Fearon，W M.D. 等。血管造影衍生的分数流储备指导经皮冠状动脉介入治疗。

The New England Journal of Medicine

《新英格兰医学杂志》

2026; DOI: 10.1056/NEJMoa2600949

2026；DOI：10.1056/NEJMoa2600949

2. H. Omori, G. Witberg, Y. Kawase, T. Tanigaki, S. Okamoto, T. Hirata, Y. Sobue, H. Ota, H. Kamiya, M. Okubo, O. Valzer, R. Kornowski, H. Matsuo. Angiogram based fractional flow reserve in patients with dual/triple vessel coronary artery disease.

2. H. Omori, G. Witberg, Y. Kawase, T. Tanigaki, S. Okamoto, T. Hirata, Y. Sobue, H. Ota, H. Kamiya, M. Okubo, O. Valzer, R. Kornowski, H. Matsuo。基于血管造影的双/三支冠状动脉疾病患者的分数流储备。

Int J Cardiol.

国际心脏病学杂志

2019 May 15:283:17-22. doi: 10.1016/j.ijcard.2019.01.072. Epub 2019 Jan 27.

2019年5月15日：283:17-22。doi：10.1016/j.ijcard.2019.01.072。Epub 2019年1月27日。

3. Witberg G, De Bruyne B, Fearon WF, Achenbach S, Engstrom T, Matsuo H, et al. Diagnostic performance of angiogram-derived fractional flow reserve: a pooled analysis of 5 prospective cohort studies.

3. Witberg G, De Bruyne B, Fearon WF, Achenbach S, Engstrom T, Matsuo H, 等。血管造影衍生的分数流储备的诊断性能：5项前瞻性队列研究的汇总分析。

JACC Cardiovasc Interv.

JACC心血管介入分册。

(2020) 13:488–97. 10.1016/j.jcin.2019.10.045

(2020) 13:488–97. 10.1016/j.jcin.2019.10.045

Contacts:

联系人：

Kara Hille

卡拉·希尔

Public Relations

公共关系

+1-763-439-6523

+1-763-439-6523

Ingrid Goldberg

英格丽德·戈德堡

Investor Relations

投资者关系

+1-763-505-2696

+1-763-505-2696

SOURCE Medtronic plc

来源：美敦力公司